GDF11 Rejuvenates Cerebrovascular Structure and Function in an Animal Model of Alzheimer’s Disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Cerebral amyloid angiopathy (CAA) is present in up to 90% of patients with Alzheimer's disease (AD), and may interact with classical neuropathology to exacerbate cognitive decline. Since growth differentiation factor 11 (GDF11) can activate vascular remodeling, we tested its effects on cognitive function and neuroinflammatory changes of AD model mice. We intravenously administered GDF11 or vehicle daily to 12-month-old transgenic mice overexpressing the amyloid-β protein precursor (AβPP)/PS1). Cognitive function was monitored using the Morris water maze, and after conclusion of the treatment, we assessed the morphology and presence of inflammatory markers in the cerebral vasculature. Subchronic treatment of adult AβPP/PS1 mice with GDF11 rescued cognitive function and ameliorated cerebrovascular function. In particular, the de novo genesis of small blood vessels and the expression of vascular-related proteins were significantly higher than in the vehicle-treated AβPP/PS1 mice, whereas the expressions of the inflammatory markers Iba-1 and GFAP significantly decreased in proportion to the lower ratio of two forms of amyloid-β (Aβ 40/42). Daily intravenous treatment with GDF11-injection can rejuvenate respects of cognition and cerebrovascular changes in AD mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice
Villeda, S. A., Plambeck, K. E., Middeldorp, J., Castellano, J. M., Mosher, K. I., Luo, J., Smith, L. K., Bieri, G., Lin, K., Berdnik, D., et al. (2014) · Nature Medicine · doi:10.1038/nm.3569 · Cited by 1,081
Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors
Katsimpardi, L., Litterman, N. K., Schein, P. A., Miller, C. M., Loffredo, F. S., Wojtkiewicz, G. R., Chen, J. W., Lee, R. T., Wagers, A. J., & Rubin, L. L. (2014) · Science · doi:10.1126/science.1251141 · Cited by 1,037 · cited 2×
“Cognitive benefits of infusions of blood from young animals are mediated by GDF11 as well as other cytokines and C-C motif Chemokine 11 (CCL11) [17, 18].”
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Self-citationCharacterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744
Alzheimer disease and cerebrovascular pathology: an update
Jellinger, K. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200068 · Cited by 680
Vascular risk factors for Alzheimer’s disease:
Breteler, M. M. B. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00110-4 · Cited by 664
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637
Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · cited 3×
“A (cid:2) PPDutch animals displaying a very high A (cid:2) 40 /A (cid:2) 42 ratio develop severe CAA, indicating that the majority of vascular amyloid deposits are composed of A (cid:2) 40 [4].”
Brain microbleeds and Alzheimer’s disease: innocent observation or key player?
Cordonnier, C., & van der Flier, W. M. (2011) · Brain · doi:10.1093/brain/awq321 · Cited by 310 · cited 2×
“The integrities of cerebrovascular architecture, capillary density, and CBF have all been reported to decline with aging [10, 11].”
Cited by
Katsimpardi, L., Kuperwasser, N., Camus, C., Moigneu, C., Chiche, A., Tolle, V., Li, H., Kokovay, E., & Lledo, P. (2020) · Aging Cell · doi:10.1111/acel.13038 · Cited by 47
“In the central nervous system, GDF11 was also shown to be neuroprotective for neurovascular recovery and neuro‐ genesis (Anqi, Ruiqi, Yanming, & Chao, 2019; Ma et al., 2018; Ozek, Krolewski, Buchanan, & Rubin, 2018; Schafer & LeBrasseur, 2019; Zhang et al., 2018).”
BackgroundThe influence of GDF11 on brain fate and function
Schafer, M. J., & LeBrasseur, N. K. (2019) · GeroScience · doi:10.1007/s11357-019-00054-6 · Cited by 39
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?
Frohlich, J., & Vinciguerra, M. (2020) · GeroScience · doi:10.1007/s11357-020-00279-w · Cited by 28
Growth differentiation factor 11 (GDF11) has pronounced effects on skin biology
Idkowiak-Baldys, J., Santhanam, U., Buchanan, S. M., Pfaff, K. L., Rubin, L. L., & Lyga, J. (2019) · PLOS ONE · doi:10.1371/journal.pone.0218035 · Cited by 28
Metadata
- Authors
- Zhang, W., Guo, Y., Li, B., Zhang, Q., Liu, J.-H., Gu, G.-J., Wang, J.-H., Bao, R.-K., Chen, Y.-J., & Xu, J.-R.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-02-20
- Volume
- 62
- Issue
- 2
- Pages
- 807-819
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2794050315
- Cited by
- 45
- References
- 14
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.